Cornerstone Pharmaceuticals
Develops small-molecule oncology therapeutics that target tumor metabolism. The company advances a lead metabolism-targeting drug candidate through preclinical studies and multi-phase clinical trials (Phase I–III) across hematologic and solid tumor indications, manages a global multisite clinical program and patient/physician resources, and pursues regulatory designations and external collaborations to support development and commercialization.
Industries
Nr. of Employees
small (1-50)
Cornerstone Pharmaceuticals
Patents
Therapeutic methods and compositions for treating pancreatic cancer using 6,8-bis-benzylthio-octanoic acid
US-11622950-B2
View Details
Therapeutic methods and compositions for treating pancreatic cancer using 6,8-bis-benzylthio-octanoic acid
US-11622950-B2
View DetailsProducts
Investigational metabolism-targeting small-molecule therapeutic (lead candidate)
A development-stage small-molecule therapeutic designed to target mitochondrial and metabolic pathways in cancer cells; evaluated in preclinical studies and multiple clinical trials as monotherapy and in combination with standard chemotherapies across hematologic and solid tumor indications.
CPI-613 (devimistat)
CPI-613 (devimistat) is a first-in-class investigational small molecule lipoate analog developed on the Altered Metabolism Directed (AMD) platform that targets cancer metabolism by selectively inhibiting PDH and KGDH enzymes in the TCA cycle.
Telaglenastat (CB-839)
A first-in-class, orally bioavailable, small molecule allosteric inhibitor of glutaminase with anti-tumor activity in preclinical models and clinical trials.
Investigational metabolism-targeting small-molecule therapeutic (lead candidate)
A development-stage small-molecule therapeutic designed to target mitochondrial and metabolic pathways in cancer cells; evaluated in preclinical studies and multiple clinical trials as monotherapy and in combination with standard chemotherapies across hematologic and solid tumor indications.
CPI-613 (devimistat)
CPI-613 (devimistat) is a first-in-class investigational small molecule lipoate analog developed on the Altered Metabolism Directed (AMD) platform that targets cancer metabolism by selectively inhibiting PDH and KGDH enzymes in the TCA cycle.
Telaglenastat (CB-839)
A first-in-class, orally bioavailable, small molecule allosteric inhibitor of glutaminase with anti-tumor activity in preclinical models and clinical trials.
Services
Coordination and execution of multicenter oncology clinical trials including site activation, enrollment tracking and safety monitoring.
Evaluation and advancement of external programs through in-licensing, out-licensing, or co-development agreements and collaboration with academic and industry partners.
Process to receive and manage physician-submitted compassionate use requests for investigational therapeutics.
Coordination and execution of multicenter oncology clinical trials including site activation, enrollment tracking and safety monitoring.
Evaluation and advancement of external programs through in-licensing, out-licensing, or co-development agreements and collaboration with academic and industry partners.
Process to receive and manage physician-submitted compassionate use requests for investigational therapeutics.
Expertise Areas
- Clinical trial management
- Oncology drug discovery and development
- Cancer metabolism therapeutics
- Regulatory strategy and designation pathways (orphan/expedited)
Key Technologies
- Metabolism-targeted small-molecule therapeutics
- Preclinical in vivo efficacy models
- Combination chemotherapy regimen development
- Global multicenter clinical trial operations
News & Updates
Coverage and expert interviews on the potential of the company's metabolic-targeting drug in metastatic pancreatic cancer.
Feature discussing metabolic approaches to targeting tumor energy production.
Review of how a metabolism-targeting program advanced to pivotal trials in AML and pancreatic cancer.
Industry coverage on the renewed interest in cancer metabolism research and related programs.
EMA granted orphan drug designation to the company's lead metabolism-targeting candidate for advanced biliary tract cancer.
FDA granted Fast Track designation to the lead candidate for treatment of acute myeloid leukemia (AML).
Coverage and expert interviews on the potential of the company's metabolic-targeting drug in metastatic pancreatic cancer.
Feature discussing metabolic approaches to targeting tumor energy production.
Review of how a metabolism-targeting program advanced to pivotal trials in AML and pancreatic cancer.
Industry coverage on the renewed interest in cancer metabolism research and related programs.
EMA granted orphan drug designation to the company's lead metabolism-targeting candidate for advanced biliary tract cancer.
FDA granted Fast Track designation to the lead candidate for treatment of acute myeloid leukemia (AML).